|
|
| | 4-{[(4E)-5-oxo-2-phenyl-4,5-dihydro-1,3-oxazol-4-ylidene]methyl}benzene-1-carboximidamide Basic information |
| | 4-{[(4E)-5-oxo-2-phenyl-4,5-dihydro-1,3-oxazol-4-ylidene]methyl}benzene-1-carboximidamide Chemical Properties |
| Boiling point | 466.982±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.308±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 11.516±0.50(predicted) | | color | White to yellow |
| | 4-{[(4E)-5-oxo-2-phenyl-4,5-dihydro-1,3-oxazol-4-ylidene]methyl}benzene-1-carboximidamide Usage And Synthesis |
| Uses | UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion[1]. | | Biological Activity | UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion[1].
UK122 (11.1, 33.3, 100 μM; 24 h) dose-dependently inhibits cell migration and significantly reduces the invasiveness of CFPAC-1 cells[1]. UK122 (10-100 μM; 48 h) has no effect of any cell growth or cell morphology change in CFPAC-1 cells[1]. | | References | [1]. Ming Zhu, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther. 2007 Apr;6(4):1348-56. |
| | 4-{[(4E)-5-oxo-2-phenyl-4,5-dihydro-1,3-oxazol-4-ylidene]methyl}benzene-1-carboximidamide Preparation Products And Raw materials |
|